sibylle loibl
sibylle loibl
Professor for medicine
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ...
Journal of clinical oncology 30 (15), 1796-1804, 2012
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
Palbociclib in hormone-receptor–positive advanced breast cancer
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
M Kaufmann, GN Hortobagyi, A Goldhirsch, S Scholl, A Makris, ...
Journal of Clinical Oncology 24 (12), 1940-1949, 2006
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study
G von Minckwitz, A Du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, ...
J Clin Oncol 27 (12), 1999-2006, 2009
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ...
The lancet oncology 15 (7), 747-756, 2014
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
Association analysis identifies 65 new breast cancer risk loci
K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ...
Nature 551 (7678), 92, 2017
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
M Untch, M Rezai, S Loibl, PA Fasching, J Huober, H Tesch, I Bauerfeind, ...
Journal of Clinical Oncology 28 (12), 2024-2031, 2010
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ...
New England Journal of Medicine 366 (4), 299-309, 2012
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
S Riethdorf, V Müller, L Zhang, T Rau, S Loibl, M Komor, M Roller, ...
Clinical cancer research 16 (9), 2634-2645, 2010
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer …
L Biganzoli, H Wildiers, C Oakman, L Marotti, S Loibl, I Kunkler, M Reed, ...
The lancet oncology 13 (4), e148-e160, 2012
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast …
M Untch, PA Fasching, GE Konecny, S Hasmüller, A Lebeau, ...
Journal of Clinical Oncology 29 (25), 3351-3357, 2011
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
M Untch, S Loibl, J Bischoff, H Eidtmann, M Kaufmann, JU Blohmer, ...
The lancet oncology 13 (2), 135-144, 2012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20